From Health Facts
Editor-In-Chief: Dr. Heidi Kussmann, ND, FABNO
Prostate cancer incidence is uncommon in men under 50 years of age. The median age of diagnosis is 68 with the incidence increasing with age. It is the third most common cancer in men and accounts for 6% of cancer deaths worldwide. The overall 5-year relative survival rate for prostate cancer is reportedly over 95%.
Prostate Cancer - Guiding Perspectives, NDNR; 2012 November|
Soy and prostate cancer: What are you telling your patients?, IHP, Nov/Dec 2009|
Assessing for prostate cancer is common in men over the 50 due to its increasing incidence. The symptoms that are normally correlated with prostate disorders include nocturia (increased urination at night), polyuria (increased urination frequency), urinary hesitancy and dysuria(painful urination).
In order to stimulate the innate ability of the body to heal the causes of disease must be identified and addressed. A detailed assessment is required to determine which factors are contributing to prostate cancer.
Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Risk of Prostate Cancer, NMJ, , 2011 November|
Aspirin Reduces the Risk of Prostate Cancer Mortality , April 2013 Natural Medicine |
Selenium & Prostate Cancer: Untangling the Web of Conflicting Data , 2010 December Natural Medicine |
Effects of Diet and Supplements on Prostate Cancer Risk, 2010 November Natural Medicine |
Chicken Skin and Eggs Increase Risk of Prostate Cancer Recurrence, 2010 June Natural Medicine |
- Chronic stress is associated with increased risk of cancer.
- In the world, demographic studies have shown that Sweden has the highest prostate cancer risk and Taiwan and Japan have the lowest risk.
- Smoking increases a person's risk of developing prostate cancer.
- Vasectomy produces anatomic, hormonal and immunologic changes and, although not substantiated by clinical studies, has been reputed to be associated with atherosclerosis, prostate cancer, testicular cancer and urolithiasis.
- Black men have the highest incidence of prostate cancer of any group.
- Familial history of prostate cancer raises risk seven times if the affected relative was diagnosed by 50 years of age, and four times if diagnosed after 70 years of age.
Early detection and screening via annual Digital Rectal Examination (DRE) and serum PSA are routine. Symptoms of urinary hesitation and dribbling, frequent night-time urination, poor urine stream, and blood at the end of urination may indicate the need to rule out prostate cancer. Diagnostic testing for prostate cancer include:
Prostate Cancer Screening, The PSA Debate Continues - Endgame 2012, Vital Link; 2012 November|
- To confirm prostate cancer it is ideal to detect the presence of hypermethylated glutathione S-transferase (GSTP1) gene as it is not hypermethylated in benign hyperplastic prostate tissue would also be helpful to rule out the false positives that occur with the PSA test. , , 
PSA Screening and Biopsy, Are They Really Necessary?, NDNR , 2011 November|
- A suggested proteomic method of biomarker detection includes identifying polypeptides secreted from human prostate cancer cells grown in culture in the presence and absence of androgen. Other markers include prostate acid phosphatase, prostate-specific membrane antigen, prostate inhibin peptide, PCA-1, PR92, prostate associated glycoprotein complex, protein-mucin antigen, 12-lipoxygenase, and p53. Further the three genes P503S, P504S, and P510S are all overexpressed in cancerous prostate tissue. 
Nomograms: Predicting 10 year probability of cancer recurrence post radical prostatectomy, IHP, , September 2010|
- If prostate cancer is suspected it is common for additional diagnostic tests to be ordered including: bone scan, pelvic CT scan, pelvic MRI or endorectal MRI or prostascint scan.
Conditions that have similar symptoms include:
The different types of prostate cancer include:
- Adenocarcinoma is the main cellular type of prostate cancer
- Small cell carcinoma
- Squamous cell carcinomas
Symptoms of prostate cancer include:
- Urinary hesitation and dribbling
- Frequent night-time urination
- Poor urine stream
- Blood at the end of urination
The goal of naturopathic treatment is to support and work in tandem with the healing power of the body. A treatment strategy is the most effective when it addresses the underlying causal factors. The treatment for prostate cancer depends on the staging (progression) of the cancer, an individual's symptoms, vitality and other conditions. The treatment strategies include: Prevention, Cancer Specific Treatments, Supportive Care and Prevent Recurrence. Many patients survive 15 years or longer with prostate cancer after diagnosis even without treatment. Also because of the advanced age of the men who develop prostate cancer they usually die from other health conditions, with prostate cancer but not because of it.
It is always advisable to work with a naturopathic doctor before engaging in any treatment plan.
Follow the general guidelines for cancer specific treatments. Additional treatments that are specific to prostate cancer include:
Follow the general guidelines for supportive care especially when conventional treatments such as surgery or radiation therapy are chosen. Specific considerations for prostate cancer include:
- The complications often seen in prostate cancer include: radiation-induced dysuria, radiation-induced urinary frequency, erectile dysfunction, hot flashes, rectal bleeding, urinary incontinence, urinary urgency, nocturia, diarrhea, or hematuria.
- ↑ 1.0 1.1 Ruddon RW (2007) Cancer Biology 4th ed. Oxford University Press, pp 442.
- ↑ Muir CS, Nectoux J, Staszwski J (1991) The epidemiology of prostate cancer. Geographical distribution and time trends. Acta Oncol;30:133-140.
- ↑ Kaul L, Heshmat MY, Kovi J, et al. (1987) The role of diet in prostate cancer. Nutr Cancer;9:123-128.
- ↑ Raspa RF (Nov 1993) Complications of vasectomy. Am Fam Physician.;48(7):1264-8. PMID: 8237740
- ↑ Lee WH et al. (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA;91:11733-7.
- ↑ Esteller M et al. (1998) Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res;58:4515-8.
- ↑ Cairns P et al. (2001) Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res;7:2727-30.
- ↑ Casciato DA. Manual of Clinical Oncology 5th ed. Lippincott Williams & Wilkins 2004. Pp 309-316.